Objective-To measure the prevalence and incidence of intermittent claudication, to describe the mortality associated with the condition, and to assess the relevance of risk factors for vascular disease. Design-A standard questionnaire on calf pain when walking was given in the prospective Speedwell study, and a range of risk factors were measured. The men were re-examined at intervals of three years, and deaths over 11 years were identified. Setting-The general population. Participants-All men aged 45 to 59 registered with 16 general practitioners. Results-The prevalence of intermittent claudication increased from almost nil at ages 45-49 to 2'9% at ages 60-64. The annual incidence increased from 0-3% in the youngest men to 0'5% in those in their early 60s. Intermittent claudication was related to the existence of ischaemic heart disease, particularly angina, at the first examination. The relative odds of men with angina developing intermittent claudication was 6*7 (95% confidence interval (95% CI) 3-6 to 12.4). The risk of death in men with intermittent claudication was substantially raised. After standardisation for age and smoking the relative odds of death was 3.8 (95% CI 2'2 to 6.5). The excess was entirely from circulatory causes. Systolic blood pressure, fasting plasma glucose, triglycerides, and white cell count were all independently associated with the development of intermittent claudication, but the most striking association was with smoking. Conclusions--Intermittent claudication is an indicator for a very high risk of death. This is only pairtly explained by its strong association with ischaemic heart disease. (Br Heart3 1994;72:128-132) 
early 60s. Intermittent claudication was related to the existence of ischaemic heart disease, particularly angina, at the first examination. The relative odds of men with angina developing intermittent claudication was 6*7 (95% confidence interval (95% CI) 3-6 to 12.4). The risk of death in men with intermittent claudication was substantially raised. After standardisation for age and smoking the relative odds of death was 3.8 (95% CI 2'2 to 6.5). The excess was entirely from circulatory causes. Systolic blood pressure, fasting plasma glucose, triglycerides, and white cell count were all independently associated with the development of intermittent claudication, but the most striking association was with smoking. Conclusions--Intermittent claudication is an indicator for a very high risk of death. This is only pairtly explained by its strong association with ischaemic heart disease. (Br Heart3 1994; 72:128-132) Intermittent claudication is a clearly defined manifestation of peripheral vascular disease. Its prevalence is low in comparison with myocardial and cerebral manifestations of probably similar disease processes.
Consequently it has been little studied and much of the epidemiological evidence comes from only a few investigations. [1] [2] [3] We report here the results of a prospective study in a representative population sample of 2348 middle aged men who have been followed up for 10 years. We describe the prevalence of the symptoms, the incidence of new symptoms during the 10 year follow up, the risk factors for the condition, and its predictive power for death.
Methods
The Speedwell prospective study began in 1979. 4 Of the 29 cases diagnosed at the baseline examination, 23 were seen at one or more of the re-examinations and 14 of them (61%) had a positive diagnosis on at least one further occasion. For comparison, 123 cases of angina were diagnosed by the same questionnaire at baseline. Of these, 93 men were seen at least once more, and 72 (77%) of them had a positive diagnosis on at least one further occasion.
INCIDENCE OF INTERMITTENT CLAUDICATION
Of the 2094 men who had no calf pain at baseline and who were examined at least once more, 84 (4 0%) had intermittent claudication on at least one of the further examinations. Twenty six men were first positive at the three year re-examination, 29 at the six year, and a further 29 at the nine to 10 year re-examination. Table 2 shows age specific incidence. As might be expected, incidence increased with age, from about 0-3% a year in those initially aged 45 to 49, to about 0 5% a year in those who were 60 to 63 at the time of the baseline examination.
INTERMITTENT CLAUDICATION AND
ISCHAEMIC HEART DISEASE Table 3 shows the incidence of intermittent claudication among men with the various manifestations of ischaemic heart disease at baseline. The odds of developing claudication were raised in men with all types of ischaemic heart disease at baseline and overall the relative odds were 3-2. The excess risk was particularly large for angina, with relative odds of 6-7. All these associations with incident claudication are highly significant (p < 0 001).
MORTALITY AND INTERMITENT CLAUDICATION
All men in the cohort were flagged with the NHS Central Registry when first recruited. To date, 414 have died after an average follow up of 11 years. Cause of death was unknown for three of these deaths. Because the numbers of men with intermittent claudication was small, we examined mortality in the 57 men who had the condition diagnosed at the first or the second examination. The figure shows survival curves for men with and without intermittent claudication. These are based on mortality from all causes, and show that survival was considerably reduced in men with intermittent claudication. Among such men mortality at five years was 30% and after 10 years it was 47%; among men without claudication the corresponding mortalities were only 6% and 14%. total triglycerides, fibrinogen, plasma viscosity, white cell count, and glucose at baseline.
There was no evidence of any association with either high density lipoprotein (HDL) cholesterol or body mass index. Many of these risk factors were interrea those with intermit-lated. To try to determine which were inde-3 8, with 95% confi-pendently associated with intermittent ) 2 2 to 6*5. The age claudication, a series of multiple logistic relative odds of death regression models were fitted, with incidence cause was 4-4 (p < of intermittent claudication as the dependent ir both all causes and variable. In models that included all three eased substantially if lipid variables, the effect of triglycerides r prevalent ischaemic remained significant (p < 0.01), whereas the luced odds of 2-7 for effect of total cholesterol became non-signifiir circulatory causes, cant. In models that included all three haemoant (p < 0 001).
static factors, the effect of white cell count deaths, the relative remained highly significant (p < 0 001) 95% CI that includes whereas the effect of fibrinogen became nonwvincing evidence that significant and that of plasma viscosity disapvere increased in men peared. Of the other variables, systolic blood cation. pressure (p < 0-05) and glucose (p < 0 05) remained significant as well as smoking habit, which was much the most powerful predictor. The association with fasting glucose concentration reflected the known association between diabetes and intermittent claudication. If the 35 known patients with diabetes were excluded from the data in table 5 the difference in mean (SEM) glucose concentration between those who developed intermittent claudication and those who did not was reduced to 0-13 (0 10) mmol/l. Exclusion of those with diabetes made no material effect on any of the other differences shown in table 5.
Discussion
Intermittent claudication is a progressive, disabling disease. In itself it is not life threatening, but as a manifestation of arterial disease its occurrence identifies a high risk group. In our cohort of 2348 middle aged men, nearly 50% of those with intermittent claudication at either the first or second examination were dead within 10 years of the diagnosis being made. Among men without claudication, 14% were dead within 10 years. This excess mortality was entirely attributable to deaths from circulatory causes, and was found consistently for every circulatory cause.
As with all studies of intermittent claudication we have found a strong association with each of the manifestations of ischaemic heart disease, but particularly with angina pectoris. This coexistence with ischaemic heart disease explains some of the increased mortality among men with intermittent claudication. This is confirmed in table 4 which shows that the relative odds of dying from any cause, or from any circulatory cause, fell substantially on adjustment for ischaemic heart disease at first examination. Even after this adjustment, both relative odds remain highly significant (p < 0.001). This implies that mortality is high among those men who have intermittent claudication but no evidence of ischaemic heart disease. Of those 24 men, seven (29%) died during the follow up. This compared with 236 (13%) of the 1833 with neither intermittent claudication nor ischaemic heart disease at first examination.
The prevalence of intermittent claudication increased sharply with age. The repeated examinations of the cohort gave estimates of prevalence of 0-8% at ages 50-54, rising to 2-9% at 60-64, and 3-8% at 65-72. These rates are consistent with the scientific literature; most reports gave prevalences of between 1 % and 4% in men of these ages.2 9 10 There are few estimates of incidence reported. Our results are based on small numbers but suggest that symptoms of claudication develop in around 0-3% of men a year in their late 40s, rising to around 0 5% of men in their early 60s. These estimates are similar to those given by the Basle" and Framingham12 studies.
Smoking is undoubtedly the most important risk factor. None of the men in our series who either had symptoms when first examined, or who developed symptoms during follow up, was a life time non-smoker. Furthermore, the incidence of new claudication was over twice as high among current smokers (6'4% during the 10 years of follow up) than among the men who were ex-smokers at first examination (2.7%). This strong association with smoking seems to be a constant finding. '3 14 Other factors that are relevant to ischaemic heart disease are also relevant to intermittent claudication. We found a positive association with systolic blood pressure, as did most'215 but not all'6 other studies. Another fairly consistent finding is a positive association with fasting glucose'217 or with diabetes mellitus. '5 We also found a positive association with fasting glucose. The situation with regard to lipids is confusing. Some studies found a positive association with total cholesterol,'216 others found a negative association with HDL cholesterol but no association with total cholesterol or triglyceride,'8 whereas others found a positive association with triglycerides and no association with HDL or low density lipoprotein cholesterol.'7 Fowkes et al reported positive univariate associations with both non-HDL cholesterol and total triglycerides. '5 On multivariate analysis the association with non-HDL cholesterol remained highly significant whereas that with triglycerides largely disappeared. Our univariate results are similar, but on multivariate analysis we found the opposite effect. Total triglyceride remained strongly associated with the incidence of intermittent claudication, whereas the effect of total cholesterol was small, and not significant. It seems likely that these differences between studies arise because of the few cases in each study due to the rarity of the condition.
Interest is developing in the relevance of thrombosis related factors to ischaemic heart disease. Most of the evidence in the scientific literature linking haemostatic factors with peripheral vascular disease is cross sectional although the Framingham study has shown fibrinogen to be predictive.'9 Raised fibrinogen concentrations have also been shown to be associated with the progression of the disease. 20 Our data on incident disease show univariate associations with fibrinogen, plasma viscosity, and white cell count (table 3) that are independent of smoking habit. Lowe et al showed cross sectional associations between peripheral arterial disease and both whole blood and plasma viscosity.2' They concluded, after multivariate analysis, that both viscosity and fibrinogen made independent contributions to peripheral arterial disease. We found that the effect of viscosity disappeared on multivariate analysis, and that the association between incident intermittent claudication and fibrinogen became non-significant. The association with white cell count, however, remained highly significant (p < 0-001). We have previously suggested that white cell count is an independent predictor for ischaemic heart disease.8 Because of this further association with the development of intermittent claudication, white cell count surely merits some further attention.
In summary, the most important aspect of intermittent claudication for clinical practice is the fact that it is a marker for a high risk of death from all circulatory causes. This arises only partly because of its coexistence with ischaemic heart disease. Mortality is also high in patients with intermittent claudication with no evidence of ischaemic heart disease.
